730 related articles for article (PubMed ID: 28987768)
21. Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.
Vaughn DJ; Bellmunt J; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Mai Y; Li H; Perini RF; Bajorin DF; de Wit R
J Clin Oncol; 2018 Jun; 36(16):1579-1587. PubMed ID: 29590008
[TBL] [Abstract][Full Text] [Related]
22. Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.
Musoro JZ; Bottomley A; Coens C; Eggermont AM; King MT; Cocks K; Sprangers MA; Groenvold M; Velikova G; Flechtner HH; Brandberg Y;
Eur J Cancer; 2018 Nov; 104():169-181. PubMed ID: 30359910
[TBL] [Abstract][Full Text] [Related]
23. Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma.
von Tresckow B; Fanale M; Ardeshna KM; Chen R; Meissner J; Morschhauser F; Moskowitz C; Zinzani PL; Giezek H; Balakumaran A; Vo TT; Raut M; Brice P
Leuk Lymphoma; 2019 Nov; 60(11):2705-2711. PubMed ID: 31012356
[TBL] [Abstract][Full Text] [Related]
24. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.
Cescon DW; Schmid P; Rugo HS; Im SA; Md Yusof M; Gallardo C; Lipatov O; Barrios CH; Perez-Garcia J; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Haiderali A; Zhou X; Guo Z; Nguyen AM; Cortes J
J Natl Cancer Inst; 2024 May; 116(5):717-727. PubMed ID: 38070159
[TBL] [Abstract][Full Text] [Related]
26. Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal.
Miguel LS; Lopes FV; Pinheiro B; Wang J; Xu R; Pellissier J; Laires PA
Value Health; 2017 Sep; 20(8):1065-1073. PubMed ID: 28964438
[TBL] [Abstract][Full Text] [Related]
27. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
Hamid O; Robert C; Daud A; Hodi FS; Hwu WJ; Kefford R; Wolchok JD; Hersey P; Joseph R; Weber JS; Dronca R; Mitchell TC; Patnaik A; Zarour HM; Joshua AM; Zhao Q; Jensen E; Ahsan S; Ibrahim N; Ribas A
Ann Oncol; 2019 Apr; 30(4):582-588. PubMed ID: 30715153
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Lupinacci R; Krepler C; Ibrahim N; Kicinski M; Marreaud S; van Akkooi AC; Suciu S; Robert C
Eur J Cancer; 2019 Jul; 116():148-157. PubMed ID: 31200321
[TBL] [Abstract][Full Text] [Related]
29. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study.
Long GV; Atkinson V; Ascierto PA; Robert C; Hassel JC; Rutkowski P; Savage KJ; Taylor F; Coon C; Gilloteau I; Dastani HB; Waxman IM; Abernethy AP
Ann Oncol; 2016 Oct; 27(10):1940-6. PubMed ID: 27405322
[TBL] [Abstract][Full Text] [Related]
30. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A
Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862
[TBL] [Abstract][Full Text] [Related]
31. Ipilimumab prolongs survival in advanced melanoma.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
[No Abstract] [Full Text] [Related]
32. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Joshua AM; Hwu WJ; Weber JS; Gangadhar TC; Joseph RW; Dronca R; Patnaik A; Zarour H; Kefford R; Hersey P; Zhang J; Anderson J; Diede SJ; Ebbinghaus S; Hodi FS
J Clin Oncol; 2018 Jun; 36(17):1668-1674. PubMed ID: 29283791
[TBL] [Abstract][Full Text] [Related]
33. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
Afzal MZ; Shirai K
J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
[TBL] [Abstract][Full Text] [Related]
34. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment.
Revicki DA; van den Eertwegh AJ; Lorigan P; Lebbe C; Linette G; Ottensmeier CH; Safikhani S; Messina M; Hoos A; Wagner S; Kotapati S
Health Qual Life Outcomes; 2012 Jun; 10():66. PubMed ID: 22694829
[TBL] [Abstract][Full Text] [Related]
35. [Severe ipilimumab-induced ulcerative colitis remitting after infliximab therapy and secondary switching with pembrolizumab].
Yelehe-Okouma M; Granel-Brocard F; Hudziak H; Schmutz JL; Gillet P
Therapie; 2018; 73(3):291-293. PubMed ID: 29203065
[No Abstract] [Full Text] [Related]
36. The use of pembrolizumab for the treatment of metastatic uveal melanoma.
Kottschade LA; McWilliams RR; Markovic SN; Block MS; Villasboas Bisneto J; Pham AQ; Esplin BL; Dronca RS
Melanoma Res; 2016 Jun; 26(3):300-3. PubMed ID: 26848796
[TBL] [Abstract][Full Text] [Related]
37. Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.
Mansoor W; Joo S; Norquist JM; Kato K; Sun JM; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Sunpaweravong P; Alsina Maqueda M; Goekkurt E; Suryawanshi S; Shah S; Shen L
Oncologist; 2024 May; ():. PubMed ID: 38815152
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma.
Yokota K; Takenouchi T; Fujisawa Y; Fukushima S; Uchi H; Inozume T; Kiyohara Y; Uhara H; Nakagawa K; Furukawa H; Han S; Watanabe M; Noguchi K; Yamazaki N
J Dermatol; 2024 May; 51(5):632-642. PubMed ID: 38529706
[TBL] [Abstract][Full Text] [Related]
39. Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab.
Shreders A; Joseph R; Peng C; Ye F; Zhao S; Puzanov I; Sosman JA; Johnson DB
Cancer Immunol Res; 2016 Jul; 4(7):569-73. PubMed ID: 27197063
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
